Design
Review
Key result
Platelet glycoprotein VI and its soluble receptor show promise as biomarkers for risk stratification in atherosclerotic diseases and as potential targets for antithrombotic therapy.
Authors
Loading...
GPVI/soluble receptor warrant prospective validation as ACS biomarkers; leaves open therapeutic potential pending randomized trials.
Platelet glycoprotein VI and its soluble form hold potential as biomarkers for early detection of ACS and as therapeutic targets for antithrombotic therapy.
Bigalke et al. (2011) conducted a review in Acute coronary syndrome and ischemic stroke. Platelet and Soluble Glycoprotein VI was evaluated. Platelet glycoprotein VI and its soluble receptor show promise as biomarkers for risk stratification in atherosclerotic diseases and as potential targets for antithrombotic therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: